Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans

(2015) Nike Müller et al.   JOURNAL OF LIPID RESEARCH

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib

(2015) Christina Charles-Schoeman et al.   Arthritis & Rheumatology

An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy

(2015) Vijay U. Rao et al.   Arthritis & Rheumatology

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator

(2013) Michael B. Boffa et al.   Current Atherosclerosis Reports

High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

(2013) A. Jamnitski et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm

(2013) Jamie Robertson et al.   Nature Reviews Rheumatology

Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis

(2012) Claire Immediato Daïen et al.   ANNALS OF THE RHEUMATIC DISEASES

Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis

(2012) Pia R. Kamstrup et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

(2011) E. Myasoedova et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

(2011) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

(2010) S. L. Westlake et al.   RHEUMATOLOGY

Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

(2010) Cheryl Barnabe et al.   ARTHRITIS CARE & RESEARCH

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

(2009) E Choy et al.   ANNALS OF THE RHEUMATIC DISEASES

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis

(2008) C A Wijbrandts et al.   ANNALS OF THE RHEUMATIC DISEASES

HDL Remodeling During the Acute Phase Response

(2008) Anisa Jahangiri et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies

(2008) J. Antonio Aviña-Zubieta et al.   ARTHRITIS AND RHEUMATISM